Crispr Therapeutics AG (NASDAQ:CRSP) – Investment analysts at William Blair dropped their Q3 2020 earnings per share (EPS) estimates for shares of Crispr Therapeutics in a research report issued to clients and investors on Tuesday, July 28th. William Blair analyst R. Prasad now expects that the company will post earnings per share of ($1.24) for the quarter, down from their previous estimate of ($1.15). William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Crispr Therapeutics’ Q4 2020 earnings at ($1.25) EPS, FY2020 earnings at ($4.91) EPS, Q1 2021 earnings at ($1.26) EPS, Q2 2021 earnings at ($1.28) EPS, Q3 2021 earnings at ($1.29) EPS, Q4 2021 earnings at ($1.30) EPS and FY2021 earnings at ($5.13) EPS.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, July 27th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.35). Crispr Therapeutics had a net margin of 6.77% and a return on equity of 2.35%. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $19.77 million. During the same quarter in the prior year, the business earned ($1.01) EPS. The company’s revenue for the quarter was down 86.2% on a year-over-year basis.

A number of other analysts also recently weighed in on CRSP. Oppenheimer initiated coverage on shares of Crispr Therapeutics in a research report on Monday, July 27th. They set a “buy” rating and a $105.00 price target for the company. Roth Capital raised their price target on shares of Crispr Therapeutics from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, June 19th. BidaskClub raised shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 9th. Chardan Capital raised their price target on shares of Crispr Therapeutics from $72.50 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, Zacks Investment Research downgraded shares of Crispr Therapeutics from a “buy” rating to a “hold” rating and set a $56.00 price objective for the company. in a report on Friday, April 24th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $90.93.

CRSP stock opened at $85.46 on Friday. Crispr Therapeutics has a twelve month low of $32.30 and a twelve month high of $97.82. The company has a market capitalization of $6.00 billion, a P/E ratio of 187.74 and a beta of 2.35. The firm has a 50 day simple moving average of $80.79 and a 200-day simple moving average of $59.93.

In other Crispr Therapeutics news, Director Bradley J. Phd Bolzon sold 20,000 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $82.39, for a total value of $1,647,800.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Rodger Novak sold 25,000 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $90.00, for a total value of $2,250,000.00. Following the completion of the sale, the president now owns 653,593 shares in the company, valued at $58,823,370. The disclosure for this sale can be found here. Insiders sold 290,214 shares of company stock worth $21,181,054 over the last quarter. 21.40% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Flagship Harbor Advisors LLC raised its stake in shares of Crispr Therapeutics by 4.2% during the second quarter. Flagship Harbor Advisors LLC now owns 3,700 shares of the company’s stock valued at $271,000 after purchasing an additional 150 shares in the last quarter. UBS Group AG raised its stake in shares of Crispr Therapeutics by 23.1% during the second quarter. UBS Group AG now owns 84,394 shares of the company’s stock valued at $6,202,000 after purchasing an additional 15,848 shares in the last quarter. M&T Bank Corp raised its stake in shares of Crispr Therapeutics by 3.9% during the second quarter. M&T Bank Corp now owns 8,423 shares of the company’s stock valued at $619,000 after purchasing an additional 314 shares in the last quarter. Stratos Wealth Partners LTD. bought a new stake in shares of Crispr Therapeutics during the second quarter valued at about $313,000. Finally, Lenox Wealth Management Inc. raised its stake in shares of Crispr Therapeutics by 77.3% during the second quarter. Lenox Wealth Management Inc. now owns 3,898 shares of the company’s stock valued at $286,000 after purchasing an additional 1,700 shares in the last quarter. Institutional investors and hedge funds own 57.93% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: What Are Cryptocurrencies?

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.